Last reviewed · How we verify
von Willebrand factor
Von Willebrand factor (vWF) is a blood glycoprotein that mediates platelet adhesion to damaged blood vessel walls and serves as a carrier protein for clotting factor VIII.
Von Willebrand factor (vWF) is a blood glycoprotein that mediates platelet adhesion to damaged blood vessel walls and serves as a carrier protein for clotting factor VIII. Used for Von Willebrand disease (Types 1, 2, and 3), Hemophilia A (as factor VIII carrier).
At a glance
| Generic name | von Willebrand factor |
|---|---|
| Also known as | Plasma-derived and/or recombinantVon Willebrand Factor (VWF) concentrates |
| Sponsor | National Center for Research Resources (NCRR) |
| Drug class | Coagulation factor replacement |
| Target | Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
vWF binds to exposed collagen and other subendothelial components at sites of vascular injury, enabling platelet adhesion and aggregation. It also stabilizes and carries factor VIII in the bloodstream, preventing its degradation and ensuring adequate coagulation capacity. Replacement therapy restores both hemostatic platelet function and factor VIII levels in patients with deficiency.
Approved indications
- Von Willebrand disease (Types 1, 2, and 3)
- Hemophilia A (as factor VIII carrier)
Common side effects
- Thrombosis
- Allergic reaction
- Injection site reactions
- Headache
Key clinical trials
- A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease (PHASE3)
- An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
- A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment of Bleeding During and After Surgery in Adults With Inherited Von Willebrand Disease in the United Kingdom (UK)
- Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement
- An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)
- Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age (PHASE3)
- External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform Analysis
- Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- von Willebrand factor CI brief — competitive landscape report
- von Willebrand factor updates RSS · CI watch RSS
- National Center for Research Resources (NCRR) portfolio CI